{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:51:43Z","timestamp":1790340703039,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grants-in-aid for the Ministry of Education, Culture, Sports, Science and Technology","award":["JP17K09531"],"award-info":[{"award-number":["JP17K09531"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12933-019-0889-y","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T12:02:53Z","timestamp":1561982573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Cardiac ischemia\u2013reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity"],"prefix":"10.1186","volume":"18","author":[{"given":"Akira","family":"Yoshii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-881X","authenticated-orcid":false,"given":"Tomohisa","family":"Nagoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Oi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu D.","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,1]]},"reference":[{"issue":"4","key":"889_CR1","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1161\/01.CIR.99.4.578","volume":"99","author":"C Depre","year":"1999","unstructured":"Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99(4):578\u201388.","journal-title":"Circulation"},{"issue":"24","key":"889_CR2","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1161\/01.CIR.103.24.2961","volume":"103","author":"R Tian","year":"2001","unstructured":"Tian R, Abel ED. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation. 2001;103(24):2961\u20136.","journal-title":"Circulation"},{"issue":"3","key":"889_CR3","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","volume":"85","author":"WC Stanley","year":"2005","unstructured":"Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85(3):1093\u2013129.","journal-title":"Physiol Rev"},{"key":"889_CR4","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.2174\/138161211798357773","volume":"17","author":"T Nagoshi","year":"2011","unstructured":"Nagoshi T, Yoshimura M, Rosano GM, Lopaschuk GD, Mochizuki S. Optimization of cardiac metabolism in heart failure. Curr Pharm Des. 2011;17:3846\u201353.","journal-title":"Curr Pharm Des"},{"issue":"411","key":"889_CR5","doi-asserted-by":"publisher","first-page":"e6084","DOI":"10.1126\/scitranslmed.aam6084","volume":"9","author":"SE Heywood","year":"2017","unstructured":"Heywood SE, Richart AL, Henstridge DC, Alt K, Kiriazis H, Zammit C, Carey AL, Kammoun HL, Delbridge LM, Reddy M, et al. High-density lipoprotein delivered after myocardial infarction increases cardiac glucose uptake and function in mice. Sci Transl Med. 2017;9(411):e6084.","journal-title":"Sci Transl Med"},{"key":"889_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijcard.2016.12.083","volume":"230","author":"L Szablewski","year":"2017","unstructured":"Szablewski L. Glucose transporters in healthy heart and in cardiac disease. Int J Cardiol. 2017;230:70\u20135.","journal-title":"Int J Cardiol"},{"issue":"6","key":"889_CR7","doi-asserted-by":"publisher","first-page":"e0130605","DOI":"10.1371\/journal.pone.0130605","volume":"10","author":"Y Kashiwagi","year":"2015","unstructured":"Kashiwagi Y, Nagoshi T, Yoshino T, Tanaka TD, Ito K, Harada T, Takahashi H, Ikegami M, Anzawa R, Yoshimura M. Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia\u2013reperfusion injury in mice. PLoS ONE. 2015;10(6):e0130605.","journal-title":"PLoS ONE"},{"issue":"3","key":"889_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1161\/01.CIR.104.3.330","volume":"104","author":"T Matsui","year":"2001","unstructured":"Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, Force TL, Franke TF, Hajjar RJ, Rosenzweig A. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 2001;104(3):330\u20135.","journal-title":"Circulation"},{"issue":"5","key":"889_CR9","doi-asserted-by":"publisher","first-page":"E789","DOI":"10.1152\/ajpendo.00564.2004","volume":"290","author":"T Matsui","year":"2006","unstructured":"Matsui T, Nagoshi T, Hong EG, Luptak I, Hartil K, Li L, Gorovits N, Charron MJ, Kim JK, Tian R, et al. Effects of chronic Akt activation on glucose uptake in the heart. Am J Physiol Endocrinol Metab. 2006;290(5):E789\u201397.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"889_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/cphy.c150016","volume":"6","author":"D Shao","year":"2015","unstructured":"Shao D, Tian R. Glucose transporters in cardiac metabolism and hypertrophy. Compr Physiol. 2015;6(1):331\u201351.","journal-title":"Compr Physiol"},{"issue":"8","key":"889_CR11","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1172\/JCI23073","volume":"115","author":"T Nagoshi","year":"2005","unstructured":"Nagoshi T, Matsui T, Aoyama T, Leri A, Anversa P, Li L, Ogawa W, Del Monte F, Gwathmey JK, Grazette L, et al. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia\/reperfusion injury. J Clin Investig. 2005;115(8):2128\u201338.","journal-title":"J Clin Investig"},{"issue":"6","key":"889_CR12","doi-asserted-by":"publisher","first-page":"H1098","DOI":"10.1152\/ajpheart.00101.2017","volume":"313","author":"AR Wende","year":"2017","unstructured":"Wende AR, Kim J, Holland WL, Wayment BE, O\u2019Neill BT, Tuinei J, Brahma MK, Pepin ME, McCrory MA, Luptak I, et al. Glucose transporter 4-deficient hearts develop maladaptive hypertrophy in response to physiological or pathological stresses. Am J Physiol Heart Circ Physiol. 2017;313(6):H1098\u2013108.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"889_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/cvr\/cvp017","volume":"82","author":"JJ Wright","year":"2009","unstructured":"Wright JJ, Kim J, Buchanan J, Boudina S, Sena S, Bakirtzi K, Ilkun O, Theobald HA, Cooksey RC, Kandror KV, et al. Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc Res. 2009;82(2):351\u201360.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"889_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/eurheartj\/ehp396","volume":"31","author":"SA Cook","year":"2010","unstructured":"Cook SA, Varela-Carver A, Mongillo M, Kleinert C, Khan MT, Leccisotti L, Strickland N, Matsui T, Das S, Rosenzweig A, et al. Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur Heart J. 2010;31(1):100\u201311.","journal-title":"Eur Heart J"},{"issue":"16","key":"889_CR15","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1161\/01.CIR.0000034049.61181.F3","volume":"106","author":"R Liao","year":"2002","unstructured":"Liao R, Jain M, Cui L, D\u2019Agostino J, Aiello F, Luptak I, Ngoy S, Mortensen RM, Tian R. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation. 2002;106(16):2125\u201331.","journal-title":"Circulation"},{"issue":"2","key":"889_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jcb.10631","volume":"90","author":"L Zhou","year":"2003","unstructured":"Zhou L, Cryan EV, D\u2019Andrea MR, Belkowski S, Conway BR, Demarest KT. Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1). J Cell Biochem. 2003;90(2):339\u201346.","journal-title":"J Cell Biochem"},{"issue":"2","key":"889_CR17","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733\u201394.","journal-title":"Physiol Rev"},{"key":"889_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","volume":"243","author":"A Di Franco","year":"2017","unstructured":"Di Franco A, Cantini G, Tani A, Coppini R, Zecchi-Orlandini S, Raimondi L, Luconi M, Mannucci E. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target. Int J Cardiol. 2017;243:86\u201390.","journal-title":"Int J Cardiol"},{"issue":"1","key":"889_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cvr\/cvp190","volume":"84","author":"SK Banerjee","year":"2009","unstructured":"Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res. 2009;84(1):111\u20138.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"889_CR20","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.yjmcc.2010.06.003","volume":"49","author":"SK Banerjee","year":"2010","unstructured":"Banerjee SK, Wang DW, Alzamora R, Huang XN, Pastor-Soler NM, Hallows KR, McGaffin KR, Ahmad F. SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy. J Mol Cell Cardiol. 2010;49(4):683\u201392.","journal-title":"J Mol Cell Cardiol"},{"issue":"9","key":"889_CR21","doi-asserted-by":"publisher","first-page":"e002183","DOI":"10.1161\/JAHA.115.002183","volume":"4","author":"R Lambert","year":"2015","unstructured":"Lambert R, Srodulski S, Peng X, Margulies KB, Despa F, Despa S. Intracellular Na+ concentration ([Na+]i) is elevated in diabetic hearts due to enhanced Na+-glucose cotransport. J Am Heart Assoc. 2015;4(9):e002183.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"889_CR22","doi-asserted-by":"publisher","first-page":"e000899","DOI":"10.1161\/JAHA.114.000899","volume":"3","author":"M Ramratnam","year":"2014","unstructured":"Ramratnam M, Sharma RK, D\u2019Auria S, Lee SJ, Wang D, Huang XY, Ahmad F. Transgenic knockdown of cardiac sodium\/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. J Am Heart Assoc. 2014;3(4):e000899.","journal-title":"J Am Heart Assoc"},{"key":"889_CR23","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1536\/ihj.17-565","volume":"59","author":"N Matsushita","year":"2018","unstructured":"Matsushita N, Ishida N, Ibi M, Saito M, Sanbe A, Shimojo H, Suzuki S, Koepsell H, Takeishi Y, Morino Y, et al. Chronic pressure overload induces cardiac hypertrophy and fibrosis via increases in SGLT1 and IL-18 gene expression in mice. Int Heart J. 2018;59:1123\u201333.","journal-title":"Int Heart J"},{"key":"889_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/cvr\/cvz037","volume":"56","author":"Z Li","year":"2019","unstructured":"Li Z, Agrawal V, Ramratnam M, Sharma RK, D\u2019Auria S, Sincoular A, Jakubiak M, Music ML, Kutschke WJ, Huang XN, et al. Cardiac sodium\u2013glucose co-transporter 1 (SGLT1) is a novel mediator of ischemia\/reperfusion injury. Cardiovasc Res. 2019;56:56. \n                    https:\/\/doi.org\/10.1093\/cvr\/cvz037\n                    \n                   (in Press).","journal-title":"Cardiovasc Res"},{"issue":"2","key":"889_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/cvr\/cvr230","volume":"92","author":"M Balteau","year":"2011","unstructured":"Balteau M, Tajeddine N, de Meester C, Ginion A, Des Rosiers C, Brady NR, Sommereyns C, Horman S, Vanoverschelde JL, Gailly P, et al. NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc Res. 2011;92(2):237\u201346.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"889_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1530\/JOE-14-0067","volume":"222","author":"T Yoshino","year":"2014","unstructured":"Yoshino T, Nagoshi T, Anzawa R, Kashiwagi Y, Ito K, Katoh D, Fujisaki M, Kayama Y, Date T, Hongo K, et al. Preconditioning actions of aldosterone through p38 signaling modulation in isolated rat hearts. J Endocrinol. 2014;222(2):289\u201399.","journal-title":"J Endocrinol"},{"key":"889_CR27","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1055\/s-0032-1316343","volume":"44","author":"T Nagoshi","year":"2012","unstructured":"Nagoshi T, Date T, Fujisaki M, Yoshino T, Sekiyama H, Ogawa K, Kayama Y, Minai K, Komukai K, Ogawa T, et al. Biphasic action of aldosterone on Akt signaling in cardiomyocytes. Horm Metab Res. 2012;44:931\u20137.","journal-title":"Horm Metab Res"},{"issue":"1","key":"889_CR28","doi-asserted-by":"publisher","first-page":"12978","DOI":"10.1038\/s41598-017-13563-1","volume":"7","author":"H Kimura","year":"2017","unstructured":"Kimura H, Nagoshi T, Yoshii A, Kashiwagi Y, Tanaka Y, Ito K, Yoshino T, Tanaka TD, Yoshimura M. The thermogenic actions of natriuretic peptide in brown adipocytes: the direct measurement of the intracellular temperature using a fluorescent thermoprobe. Sci Rep. 2017;7(1):12978.","journal-title":"Sci Rep"},{"issue":"5","key":"889_CR29","doi-asserted-by":"publisher","first-page":"H2504","DOI":"10.1152\/ajpheart.00322.2006","volume":"291","author":"GD Thakker","year":"2006","unstructured":"Thakker GD, Frangogiannis NG, Bujak M, Zymek P, Gaubatz JW, Reddy AK, Taffet G, Michael LH, Entman ML, Ballantyne CM. Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;291(5):H2504\u201314.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"12","key":"889_CR30","doi-asserted-by":"publisher","first-page":"H1530","DOI":"10.1152\/ajpheart.00008.2015","volume":"308","author":"T Aoyagi","year":"2015","unstructured":"Aoyagi T, Higa JK, Aoyagi H, Yorichika N, Shimada BK, Matsui T. Cardiac mTOR rescues the detrimental effects of diet-induced obesity in the heart after ischemia\u2013reperfusion. Am J Physiol Heart Circ Physiol. 2015;308(12):H1530\u20139.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"22","key":"889_CR31","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"889_CR32","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"889_CR33","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"1","key":"889_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12933-017-0638-z","volume":"16","author":"J Russell","year":"2017","unstructured":"Russell J, Du Toit EF, Peart JN, Patel HH, Headrick JP. Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection. Cardiovasc Diabetol. 2017;16(1):155.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"889_CR35","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy. Circ Res. 2018;122(4):624\u201338.","journal-title":"Circ Res"},{"issue":"4","key":"889_CR36","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/cvr\/cvx018","volume":"113","author":"CR Chong","year":"2017","unstructured":"Chong CR, Clarke K, Levelt E. Metabolic remodeling in diabetic cardiomyopathy. Cardiovasc Res. 2017;113(4):422\u201330.","journal-title":"Cardiovasc Res"},{"issue":"9\u201310","key":"889_CR37","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1242\/dmm.001941","volume":"2","author":"H Bugger","year":"2009","unstructured":"Bugger H, Abel ED. Rodent models of diabetic cardiomyopathy. Dis Model Mech. 2009;2(9\u201310):454\u201366.","journal-title":"Dis Model Mech"},{"issue":"1","key":"889_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12933-018-0741-9","volume":"17","author":"KA Connelly","year":"2018","unstructured":"Connelly KA, Zhang Y, Desjardins J-F, Thai K, Gilbert RE. Dual inhibition of sodium\u2013glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. Cardiovasc Diabetol. 2018;17(1):99.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"889_CR39","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.bbrc.2016.02.016","volume":"472","author":"A Kanwal","year":"2016","unstructured":"Kanwal A, Nizami HL, Mallapudi S, Putcha UK, Mohan GK, Banerjee SK. Inhibition of SGLT1 abrogates preconditioning-induced cardioprotection against ischemia\u2013reperfusion injury. Biochem Biophys Res Commun. 2016;472(2):392\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"889_CR40","first-page":"6887","volume":"17","author":"L Meng","year":"2018","unstructured":"Meng L, Uzui H, Guo H, Tada H. Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts. Mol Med Rep. 2018;17(5):6887\u201392.","journal-title":"Mol Med Rep"},{"issue":"1","key":"889_CR41","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1074\/jbc.M113.526814","volume":"289","author":"JR Zapata-Morales","year":"2014","unstructured":"Zapata-Morales JR, Galicia-Cruz OG, Franco M, Martinez YMF. Hypoxia-inducible factor-1alpha (HIF-1alpha) protein diminishes sodium glucose transport 1 (SGLT1) and SGLT2 protein expression in renal epithelial tubular cells (LLC-PK1) under hypoxia. J Biol Chem. 2014;289(1):346\u201357.","journal-title":"J Biol Chem"},{"issue":"10","key":"889_CR42","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects, potential mechanisms and clinical applications. Circulation. 2016;134(10):752\u201372.","journal-title":"Circulation"},{"issue":"1","key":"889_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12933-018-0745-5","volume":"17","author":"S Lahnwong","year":"2018","unstructured":"Lahnwong S, Chattipakorn SC, Chattipakorn N. Potential mechanisms responsible for cardioprotective effects of sodium\u2013glucose co-transporter 2 inhibitors. Cardiovasc Diabetol. 2018;17(1):101.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"889_CR44","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/cvr\/cvy295","volume":"115","author":"KL Chin","year":"2019","unstructured":"Chin KL, Ofori-Asenso R, Hopper I, von Lueder TG, Reid CM, Zoungas S, Wang BH, Liew D. Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. Cardiovasc Res. 2019;115(2):266\u201376.","journal-title":"Cardiovasc Res"},{"key":"889_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz004","author":"L Uthman","year":"2019","unstructured":"Uthman L, Nederlof R, Eerbeek O, Baartscheer A, Schumacher C, Buchholtz N, Hollmann MW, Coronel R, Weber NC, Zuurbier CJ. Delayed ischemic contracture onset by empagliflozin associates with NHE-1 inhibition and is dependent on insulin in isolated mouse hearts. Cardiovasc Res. 2019. \n                    https:\/\/doi.org\/10.1093\/cvr\/cvz004\n                    \n                   (in Press).","journal-title":"Cardiovasc Res"},{"issue":"3","key":"889_CR46","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia. 2018;61(3):722\u20136.","journal-title":"Diabetologia"},{"issue":"3","key":"889_CR47","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2016","unstructured":"Baartscheer A, Schumacher CA, Wust RC, Fiolet JW, Stienen GJ, Coronel R, Zuurbier CJ. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits. Diabetologia. 2016;60(3):568\u201373.","journal-title":"Diabetologia"},{"key":"889_CR48","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","volume":"104","author":"TM Lee","year":"2017","unstructured":"Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298\u2013310.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"889_CR49","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","volume":"13","author":"B Lin","year":"2014","unstructured":"Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim-Mitsuyama S. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13(1):148.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"889_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","volume":"15","author":"H Kusaka","year":"2016","unstructured":"Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016;15(1):157.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"889_CR51","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2337\/db16-0733","volume":"66","author":"M Joubert","year":"2017","unstructured":"Joubert M, Jagu B, Montaigne D, Marechal X, Tesse A, Ayer A, Dollet L, Le May C, Toumaniantz G, Manrique A, et al. The sodium\u2013glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes. 2017;66(4):1030\u201340.","journal-title":"Diabetes"},{"issue":"1","key":"889_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","volume":"16","author":"J Habibi","year":"2017","unstructured":"Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16(1):9.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"889_CR53","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","volume":"3","author":"S Verma","year":"2018","unstructured":"Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, Dyck JE, Uddin GM, Oudit GY, Mayoux E, et al. Empagliflozin increases cardiac energy production in diabetes. JACC Basic Transl Sci. 2018;3(5):575\u201387.","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"889_CR54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/JOE-17-0457","volume":"236","author":"P Tanajak","year":"2018","unstructured":"Tanajak P, Sa-Nguanmoo P, Sivasinprasasn S, Thummasorn S, Siri-Angkul N, Chattipakorn SC, Chattipakorn N. Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia\u2013reperfusion injury. J Endocrinol. 2018;236(2):69\u201384.","journal-title":"J Endocrinol"},{"issue":"1","key":"889_CR55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","volume":"18","author":"DD Adingupu","year":"2019","unstructured":"Adingupu DD, Gopel SO, Gronros J, Behrendt M, Sotak M, Miliotis T, Dahlqvist U, Gan LM, Jonsson-Rylander AC. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob(\u2212\/\u2212) mice. Cardiovasc Diabetol. 2019;18(1):16.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"889_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Lu Y, Cheng Y, Li T, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15.","journal-title":"Cardiovasc Diabetol"},{"issue":"24","key":"889_CR57","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"4","key":"889_CR58","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334.","journal-title":"N Engl J Med"},{"issue":"17","key":"889_CR59","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","volume":"139","author":"M Sano","year":"2019","unstructured":"Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019;139(17):1985\u20137.","journal-title":"Circulation"},{"issue":"21","key":"889_CR60","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1161\/CIRCULATIONAHA.108.832915","volume":"119","author":"J Yan","year":"2009","unstructured":"Yan J, Young ME, Cui L, Lopaschuk GD, Liao R, Tian R. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation. 2009;119(21):2818\u201328.","journal-title":"Circulation"},{"issue":"1","key":"889_CR61","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ab.2012.07.003","volume":"429","author":"A Kanwal","year":"2012","unstructured":"Kanwal A, Singh SP, Grover P, Banerjee SK. Development of a cell-based nonradioactive glucose uptake assay system for SGLT1 and SGLT2. Anal Biochem. 2012;429(1):70\u20135.","journal-title":"Anal Biochem"},{"issue":"2","key":"889_CR62","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/eurjhf\/hfp191","volume":"12","author":"D von Lewinski","year":"2010","unstructured":"von Lewinski D, Gasser R, Rainer PP, Huber MS, Wilhelm B, Roessl U, Haas T, Wasler A, Grimm M, Bisping E, et al. Functional effects of glucose transporters in human ventricular myocardium. Eur J Heart Fail. 2010;12(2):106\u201313.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"889_CR63","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.metabol.2009.10.025","volume":"59","author":"D von Lewinski","year":"2010","unstructured":"von Lewinski D, Rainer PP, Gasser R, Huber MS, Khafaga M, Wilhelm B, Haas T, Machler H, Rossl U, Pieske B. Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients. Metabolism. 2010;59(7):1020\u20138.","journal-title":"Metabolism"},{"issue":"1","key":"889_CR64","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/jpet.116.232025","volume":"358","author":"R Ohgaki","year":"2016","unstructured":"Ohgaki R, Wei L, Yamada K, Hara T, Kuriyama C, Okuda S, Ueta K, Shiotani M, Nagamori S, Kanai Y. Interaction of the sodium\/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther. 2016;358(1):94\u2013102.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"889_CR65","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.2337\/db07-1472","volume":"57","author":"S Han","year":"2008","unstructured":"Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723\u20139.","journal-title":"Diabetes"},{"issue":"9","key":"889_CR66","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.2337\/db16-0058","volume":"65","author":"SA Hawley","year":"2016","unstructured":"Hawley SA, Ford RJ, Smith BK, Gowans GJ, Mancini SJ, Pitt RD, Day EA, Salt IP, Steinberg GR, Hardie DG. The Na+\/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65(9):2784\u201394.","journal-title":"Diabetes"},{"issue":"2","key":"889_CR67","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.bbrc.2003.12.090","volume":"314","author":"K Elfeber","year":"2004","unstructured":"Elfeber K, Stumpel F, Gorboulev V, Mattig S, Deussen A, Kaissling B, Koepsell H. Na(+)-d-glucose cotransporter in muscle capillaries increases glucose permeability. Biochem Biophys Res Commun. 2004;314(2):301\u20135.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0889-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-019-0889-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0889-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T23:05:03Z","timestamp":1593471903000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0889-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,1]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["889"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0889-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,1]]},"assertion":[{"value":"22 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal procedures conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Animal Research Committee at the Jikei University School of Medicine (2016-038C4).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Michihiro Yoshimura reports that there are any relevant conflicts of interest. Outside the submitted work, there are personal fees from Mochida Pharmaceutical Co., Ltd, personal fees from MSD K.K., grants and personal fees from Kyowa Hakko Kirin Co., Ltd., grants and personal fees from Pfizer Japan Inc., grants and personal fees from Daiichi Sankyo Healthcare Co., Ltd., grants and personal fees from Sumitomo Dainippon Pharma Co., Ltd., grants from Nippon Boehringer Ingelheim Co., Ltd., grants from Otsuka Pharmaceutical Co., Ltd., grants from Teijin Pharma Limited, personal fees from Fujiyakuhin Co., Ltd., grants and personal fees from AstraZeneca K.K., personal fees from Taisho Toyama Pharmaceutical Co., Ltd., grants from Astellas Pharma Inc., personal fees from Mitsubishi Tanabe Pharma Corporation, grants from Shionogi & Co., Ltd., grants from Ono Pharmaceutical Co., Ltd. Tomohisa Nagoshi also reports that there are any relevant conflicts of interest. Outside the submitted work, there are grants from Daiichi Sankyo Healthcare Co., Ltd., from Nippon Boehringer Ingelheim Co., Ltd., and from Mitsubishi Tanabe Pharma Corporation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}